The Virtue® Sirolimus-Eluting Balloon (SEB) is a First-In-ClassDrug-Eluting Balloon Angioplasty System for the Treatment of Coronary Artery Disease.
- Novel, patented, first in-class device that delivers sirolimus, the proven gold standard drug for preventing restenosis of treated arteries, to the vessel wall during balloon angioplasty without the need for a permanent implant
- Compelling efficacy and safety data from the European multi-center prospective clinical trial, SABRE, out to 3 years
- Aims to be the first approved drug-eluting balloon product for coronary use in the U.S.
- Along with coronary ISR, Virtue® SEB has significant follow-on clinical indications such as treatment of small (<2.75mm) vessels, bifurcated lesions, below-the-knee lesions and others